Prostate cancer research has been greatly hindered by the paucity of new investigators entering into the field. In recognition of the need to help establish independently funded investigators in the field of translational prostate cancer research, the UM Prostate SPORE has supported two to three junior faculty per year. The focus of the Career Development Program (CDP) is to provide investigators the resources to generate preliminary data for subsequent NIH ROI grant applications. The UM Prostate SPORE commits $70,000 annually per investigator. Career Development awardees are funded for a maximum of two years, subject to annual review. The awardees'departments supply another $10,000 per year in matching funds. Investigators, many of whom are outside the field of prostate cancer, meet quarterly with Drs. Cooney and Robins who act as clinical resource and basic science mentors, respectively. A former CDP investigator. Dr. Cooney is a medical oncologist with appointments in internal medicine and urology. Dr. Cooney is the

Public Health Relevance

The UM Prostate SPORE continues to emphasize the importance of the CDP as an integral part of the of our prostate cancer research community. Through a process of rigorous peer review, we continue to encourage innovative and high risk / high reward prostate cancer research by new investigators to the field while providing them a supportive mentoring environment. Our ultimate goal is to decrease the morbidity and mortality of prostate cancer through innovative research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA186786-01
Application #
8788158
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Project Start
2014-09-11
Project End
2019-08-31
Budget Start
2014-09-11
Budget End
2015-08-31
Support Year
1
Fiscal Year
2014
Total Cost
$94,671
Indirect Cost
$33,630
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Udager, Aaron M; DeMarzo, Angelo M; Shi, Yang et al. (2016) Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics. Prostate 76:845-53
Kaushik, Akash K; Shojaie, Ali; Panzitt, Katrin et al. (2016) Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer. Nat Commun 7:11612
Feng, Felix Y; Kothari, Vishal (2016) Driven to metastasize: Kinases as potential therapeutic targets in prostate cancer. Proc Natl Acad Sci U S A 113:473-5
Allen, Eliezer M Van; Robinson, Dan; Morrissey, Colm et al. (2016) A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: Implications for precision cancer medicine. Oncotarget :
Niknafs, Yashar S; Han, Sumin; Ma, Teng et al. (2016) The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. Nat Commun 7:12791
Fabris, Linda; Ceder, Yvonne; Chinnaiyan, Arul M et al. (2016) The Potential of MicroRNAs as Prostate Cancer Biomarkers. Eur Urol 70:312-22
Shukla, Sudhanshu; Zhang, Xiang; Niknafs, Yashar S et al. (2016) Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer. Neoplasia 18:489-99
Tomlins, Scott A; Day, John R; Lonigro, Robert J et al. (2016) Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol 70:45-53
Roychowdhury, Sameek; Chinnaiyan, Arul M (2016) Translating cancer genomes and transcriptomes for precision oncology. CA Cancer J Clin 66:75-88
Day, Kathleen C; Lorenzatti Hiles, Guadalupe; Kozminsky, Molly et al. (2016) HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone. Cancer Res :

Showing the most recent 10 out of 45 publications